In This Issue
Cancer Discov March 1 2019 9 (3) 305-308; DOI:10.1158/2159-8290.CD-ITI9-3
The recurrent BCL2 Gly101Val point mutation decreases binding to the BCL2 inhibitor venetoclax and mediates acquired resistance in patients with chronic lymphocytic leukemia.
Combined treatment with tamoxifen and the BCL2 inhibitor venetoclax is safe and shows clinical activity in patients with ER+ and BCL2+ metastatic breast cancer.
The addition of immune checkpoint blockade to hypomethylating therapy is safe and effective in patients with acute myeloid leukemia.
The VEGFR-sparing multikinase RET inhibitor RXDX-105 exhibits antitumor activity and inhibition of RET in patients with non-KIF5B–RET non–small cell lung cancer.
Combined BRAF and MEK inhibition induces ER translocation of MAPK pathway components, followed by ERK reactivation and induction of autophagy.
Increased utilization of acetyl-CoA promotes plasticity in Kras-mutant pancreatic cells and renders PDAC sensitive to inhibitors of the BET family of proteins and HMG-CoA reductase.
PHF6 loss-of-function is an early event in T-ALL development that facilitates leukemic initiation by promoting HSC expansion and selfrenewal.